| Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer. | |
| | |
MedLine Citation:
|
PMID: 21165551 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
This study describes a combined gene and cell therapy based on the genetic modification of primary human macrophages, as a treatment for cancer. Here, we have utilised the tumour-infiltrating properties of macrophages as vehicles to deliver a gene encoding a prodrug-activating enzyme such as human cytochrome P450 2B6 (CYP2B6) inside tumours followed by killing the tumour cells with the prodrug cyclophosphamide (CPA). Macrophages were transduced with an adenoviral vector that expresses human cytochrome CYP2B6 via a synthetic hypoxia responsive promoter (OBHRE) and with human P450 reductase (P450R), via the CMV promoter. In the presence of CPA, these genetically modified macrophages showed increased cytotoxicity against various tumour cell lines compared to untransduced macrophages or macrophages transduced with CYP2B6 alone. In human ovarian carcinoma xenograft models, the median survival of mice treated with genetically modified macrophages plus CPA increased up to two-fold compared to the survival of mice treated with untransduced macrophages and CPA. Genetically modified autologous macrophages may be a feasible therapeutic option for the treatment of some solid tumours, such as ovarian cancer. |
| | |
Authors:
|
On Kan; Debbie Day; Sharifah Iqball; Frances Burke; Matthew J Grimshaw; Stuart Naylor; Katie Binley |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-12-15 |
Journal Detail:
|
Title: International journal of molecular medicine Volume: 27 ISSN: 1791-244X ISO Abbreviation: Int. J. Mol. Med. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2010-12-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9810955 Medline TA: Int J Mol Med Country: Greece |
Other Details:
|
Languages: eng Pagination: 173-80 Citation Subset: IM |
Affiliation:
|
Oxford BioMedica (UK) Ltd., Medawar Centre, Oxford Science Park, Oxford, UK. o.kan@oxfordbiomedica.co.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tiny percutaneous needle biopsy: An efficient method for studying cellular and molecular aspects of ...
Next Document: Detection of soluble HFE associated with soluble transferrin receptor in human serum.